ReviewPain research & management2026
Towards Restoring Dopaminergic Balance in Fibromyalgia: The Untapped Potential of Nonpharmacological Interventions.
Review in Pain research & management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibromyalgia (FM) is a chronic syndrome characterized by widespread pain, cognitive dysfunction, and mood disturbances. Growing evidence suggests that dopaminergic dysregulation may play a role in the pathophysiology of FM, linking reduced dopamine function to altered pain perception, anhedonia, fatigue, and impaired cognition. While pharmacological treatments-such as duloxetine, milnacipran, and pregabalin-may influence dopamine only indirectly, dopaminergic agonists like pramipexole have shown partial efficacy. Nonpharmacological interventions, including exercise, mindfulness, cognitive behavioral therapy (CBT), and noninvasive brain stimulation (NIBS), consistently improve symptoms, but their potential impact on dopamine pathways remains largely unexplored. This narrative-short review highlights a critical knowledge gap regarding dopaminergic modulation by nonpharmacological strategies and proposes a paradigm shift to be tested in future FM research. Future longitudinal, multimodal studies integrating neuroimaging, dopaminergic biomarkers, and clinical outcomes are required to test whether combined interventions exert synergistic effects on dopamine circuits. The validation of dopaminergic biomarkers to stratify patients according to their individual neurobiological profiles represents a critical step toward transitioning from a 'one-size-fits-all' approach to a precision medicine paradigm, enabling the development of tailored interventions aimed at restoring dopaminergic balance and, ultimately, improving pain, mood, cognition, and quality of life in FM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.